Page 1

Gilead Sciences (GILD)

Price: $45.99

Industry: Drugs Chaikin Power Gauge Report | Generated: Wed Feb 29 11:41 EST 2012 Power Gauge Rating

GILD - Bullish TM

The Chaikin Power Gauge Rating for GILD is bullish due to very bullish price/volume activity and strong earnings performance. Price and volume activity for GILD is very bullish which is indicated by positive Chaikin money flow and an increasing volume trend.

News Sentiment Rating

Bullish GILD Gilead Scien..

February 24, 2012

TM

Chaikin Sentiment Gauge for GILD is bullish. There is currently a significant positive sentiment within news stories concerning GILD.

News Sentiment :Positive

Power Trend - 5 Year Chart

The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

High Potential

Neutral

Low Potential

www.chaikinpowertools.com


Financials & Earnings

Financial Metrics Rating

Financial Metrics

Neutral

LT Debt/Equity Ratio

GILD's financial metrics are neutral. The company yields a high return on shareholder's equity and is carrying too much long term debt relative to its industry group.

Price to Book Value

Return on Equity

The rank is based on a high long term debt to equity ratio relative to its industry group, high price to book value ratio, high return on equity and relatively high cash flow.

Price to Sales Ratio

Business Value

Assets and Liabilities

Valuation

Returns

Ratio

TTM

Ratio

TTM

Ratio

Current Ratio

5.53

Price/Book

5.03

Return on Invest

25.6%

LT Debt/Equity

1.13

Price/Sales

4.12

Return on Equity

45.4%

Earnings Performance

TTM

Earnings Performance Rating

Bullish

Earnings Growth

GILD's earnings performance has been strong. The company is priced relatively low compared to next year's projected EPS and has a stable 5 year earnings trend.

Earnings Surprise

Earnings Trend

The rank is based on worse than expected earnings in recent quarters, a relatively low projected P/E ratio and consistent earnings over the past 5 years.

Projected P/E Ratio

Earnings Consistency

5 Year Revenue and Earnings Growth

Revenue(M) Rev % Growth EPS EPS % Growth

EPS Estimates

12/07

12/08

12/09

12/10

12/11

4,230.04

5,335.75

7,011.38

7,949.42

8,385.38

39.78%

26.14%

31.40%

13.38%

5.48%

$1.74

$2.18

$2.91

$3.39

$3.62

234.36%

25.29%

33.49%

16.49%

6.78%

EPS Surprise

Factor

Actual EPS Prev

EST EPS Current

Change

$0.82

$0.92

+0.10

Quarterly EPS Yearly EPS Factor

$3.62

$3.68

+0.06

Actual EPS Growth

Est EPS Growth

Change

23.24%

14.57%

-8.67

3-5 year EPS

EPS Quarterly Results Estimate

Actual

Difference

% Difference

FY

Qtr 1

Qtr 2

Qtr 3

Qtr 4

Total

Latest Qtr

$1.00

$0.92

$-0.08

1 Qtr Ago

$0.96

$0.97

$0.01

-8.00

12/09

$0.65

$0.63

$0.75

$0.89

$2.92

1.04

12/10

$0.95

$0.81

$0.85

$0.78

$3.39

2 Qtr Ago

$0.96

$0.95

3 Qtr Ago

$0.92

$0.82

$-0.01

-1.04

12/11

$0.82

$0.95

$0.97

$0.88

$3.62

$-0.10

-10.87

Fiscal Year End Month is December.

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

www.chaikinpowertools.com


Price Trend & Expert Opinions Price/Volume Activity

Price/Volume Activity Rating

Very Bullish

Relative Strength vs Market

Price and volume activity for GILD is very bullish. GILD is experiencing sustained buying and is trading on higher volume than its 90 day average volume.

Chaikin Money Flow

Price Trend

The rank for GILD is based on positive Chaikin money flow, a negative Chaikin price trend ROC and an increasing volume trend.

Price Trend ROC

Volume Trend

Relative Strength vs S&P500 Index

Chaikin Money Flow

Chart shows whether GILD is performing better or worse than the market.

Chaikin Money Flow analyzes supply and demand for a company's stock.

Price Activity

Price Activity

Volume Activity

Factor

Value

Factor

52 Week High

56.02

% Change Price - 4 Weeks

-5.85%

Average Volume 20 Days

13,973,421

52 Week Low

35.34

% Change Price - 24 Weeks

20.39%

Average Volume 90 Days

10,207,012

% Change Price - 4 Wks Rel to S&P

-9.95%

Chaikin Money Flow Persistency

% Change Price - 24 Wks Rel to S&P

2.90%

% Change YTD Rel S&P 500

1.82%

Expert Opinions

Value

Factor

Value

91%

Expert Opinions

Neutral

Earnings Estimate Revisions

Expert opinions about GILD are neutral. Analysts's opinions on GILD have been more positive recently and analysts are lowering their EPS estimates for GILD.

Short Interest

Insider Activity

The rank for GILD is based on analysts revising earnings estimates downward, a low short interest ratio, insiders purchasing stock and optimistic analyst opinions.

Analyst Opinions

Relative Strength vs Industry

Earnings Estimate Revisions Current Current Qtr Next Qtr

0.92 0.92 Current

Current FY

3.68

Analyst Recommendations

7 Days Ago % Change 0.92 0.92

0.00% 0.00%

30 Days Ago % Change 3.94

-0.26

EPS Estimates Revision Summary

Factor

Value

Mean this Week Mean Last Week

Strong Buy +0.08

Last 4 Weeks

Down

Up

Down

Curr Qtr

0

0

0

2

Curr Yr

0

0

1

5

Next Qtr

0

0

0

2

Next Yr

0

0

0

6

Buy

Change Mean 5 Weeks Ago

Last Week Up

Strong Buy

I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here

www.chaikinpowertools.com


The Company & Its Competitors

News Headlines for GILD

GILD's Competitors in Drugs Company

Power Gauge

Historic EPS growth

Projected EPS growth

Profit Margin

PEG

PE

Revenue(M)

23.24%

14.57%

33.44%

0.86

12.57

8,385

AMGN

1.80%

9.40%

23.64%

1.22

13.01

15,582

CELG

40.88%

22.74%

27.22%

0.74

21.50

4,842

VRTX

172.54%

-

2.10%

-

-

1,411

13.80%

13.05%

24.45%

1.46

19.98

5,049

-29.67%

-

-1050.95%

-

-

9,565

GILD

BIIB SVNT

U.S. FDA Grants Priority Review for TruvadaŽ for Reducing the Risk of Acquiring HIV Infection - Feb 13, 2012 Gilead Sciences jumps on hepatitis C data - Feb 3, 2012 Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Form - Jan 18, 2012 Gilead Sciences Completes Acquisition of Pharmasset, In - Jan 17, 2012 Gilead nears completion of Pharmasset deal Jan 12, 2012

Company Details

Company Profile

Gilead Sciences 333 LAKESIDE DR FOSTER CITY, CA 94404 USA Phone: 6505743000 Fax: 650-578-9264 Website: http://http://www.gilead.com Full Time Employees: 4,000 Sector: Medical

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.

Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.

LM 2.3 DS 3.0 LS 2.1

Data Provided by ZACKS Investment Research, Inc., www.zacks.com

Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com

Stock Research Report for GILD as of 2/29/12 - Chaikin Power Tools  

To order a free Chaikin Power Gauge stock research report for GILD go to

Read more
Read more
Similar to
Popular now
Just for you